I am a board-certified hematologist-oncologist, and my clinical activity and research focus on stem cell transplantation for patients with blood disorders. I trained and worked for many years at the University of Texas M.D. Anderson Cancer Center, where I was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, I joined the faculty of Memorial Sloan Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service.
My research focus has been on improving treatments for older patients who have acute and chronic leukemia. My colleagues and I pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers. Before this discovery, older patients with these diseases were rarely considered candidates for stem cell transplantation procedures using donor cells because of the toxic effects of high-dose chemotherapy. The development of these less intense and less toxic regimens has allowed us to perform transplants for older patients in a safe and effective manner and has changed the standard of care throughout the world. I plan to continue this research in the context of the pioneering T cell depletion techniques developed at Memorial Sloan Kettering. This new approach has dramatically reduced the risk of graft-versus-host disease, a serious complication of donor stem cell transplantation. Disease recurrence after transplantation remains an important cause of treatment failure, and I am a proponent of post-transplant maintenance therapies using a variety of targeted therapies, which we are continuing to explore at Memorial Sloan Kettering.
I am an expert in the treatment of multiple myeloma, a blood cancer that affects plasma cells (the cells that produce the antibodies that protect us against infections). My research in this area has focused on developing new conditioning regimens for autologous transplant, a treatment approach in which patients receive an infusion of their own stem cells or bone marrow following a course of high-dose chemotherapy, as well as developing strategies that will reduce “symptom burden” and make the treatment so tolerable that it can be done on an outpatient basis. Our goal is to deliver the most effective therapies with minimum symptom burden. I led the Myeloma Intergroup Committee of the Blood and Marrow Clinical Trials Network, which developed the current national study looking at the role of consolidation therapy after autologous stem cell transplant for patients with myeloma.
As a strong believer in collaborative science among large academic centers, I have been involved in many multi-institutional projects and until recently chaired the executive board of the Center for International Blood and Marrow Transplant Research. I am also the past chair of the steering committee of the Blood and Marrow Transplant Clinical Trials Network, a federally funded group that defines the research agenda for stem cell transplantation in the United States.
- Clinical Expertise: Bone Marrow and/or Stem Cell Transplantation for Blood Disorders; Treatment of Multiple Myeloma, Leukemias, and Lymphomas
- Awards and Honors: New York Magazine Top Doctors (2016)
- Languages Spoken: English; Spanish
- Education: MD, Universidad Central de Venezuela
- Residencies: Good Samaritan Hospital (Cincinnati, Ohio)
- Fellowships: University of Texas MD Anderson Cancer Center
- Board Certifications: Internal Medicine; Hematology; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Sergio A. Giralt
- A Phase I/II Study of Vadastuximab Talirine Given Before or After Stem Cell Transplantation in Patients with Recurrent or Persistent Acute Myeloid Leukemia (AML)
- A Phase II Study of Ixazomib as Maintenance Treatment after Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma
Clinical Trials Co-Investigated by Sergio A. Giralt
- A Phase I Study of an mRNA-Modified Dendritic Cell Vaccine in Patients with Multiple Myeloma as Consolidation Treatment after Autologous Stem Cell Transplantation
- A Phase I Study of Elotuzomab with Either Lirilumab or Urelumab in Patients with Multiple Myeloma
- A Phase I/II Study of Pomalidomide and Dexamethasone with and without Ixazomib in Patients with Recurrent Multiple Myeloma
- A Phase I/IIA Study of Carfilzomib plus High-Dose Melphalan Before Autologous Stem Cell Transplant in Patients with Multiple Myeloma
- A Phase IB Study of SAR650984 with Lenalidomide and Dexamethasone to Treat Recurrent or Persistent Multiple Myeloma
- A Phase II Study Assessing the Impact of Stem Cell Dose on Progression-Free Survival in Patients Receiving High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Recurrent or Persistent Diffuse Large B-Cell Lymphoma
- A Phase II Study of Romidepsin after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
- A Pilot Study of the Wilms' Tumor 1 (WT1) Analog Peptide Vaccine in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation
- Pilot Study of Homebound Stem Cell Transplantation for Patients with Multiple Myeloma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more